AstraZeneca recently announced that its New Drug Application for Baxdrostat (No. 1428652-17-8) has been accepted for priority review by the U.S. Food and Drug Administration. The PDUFA target action date is expected in the second quarter of 2026. Baxdrostat is an oral small-molecule, first-in-class, highly selective aldosterone synthase inhibitor (ASI) designed to complement existing therapies and provide a new treatment option for patients with resistant hypertension who remain uncontrolled despite multiple antihypertensive agents.

Clinical evidence indicates that Baxdrostat achieved consistent and clinically meaningful blood-pressure reductions in two pivotal Phase III studies. In the BaxHTN trial, among patients whose blood pressure remained inadequately controlled despite multi-drug therapy, the 1 mg and 2 mg doses lowered seated systolic blood pressure by approximately 14.5 mmHg and 15.7 mmHg from baseline, respectively. After placebo adjustment, the net reduction was about 8.7 mmHg and 9.8 mmHg, compared with only 5.8 mmHg in the placebo group. Baxdrostat met both primary and secondary endpoints, with the 2 mg dose demonstrating a more sustained effect and a higher proportion of patients achieving target systolic blood pressure below 130 mmHg.

The subsequent Bax24 study employed 24-hour ambulatory blood pressure monitoring (ABPM) as the primary endpoint, further confirming the agent’s around-the-clock efficacy. A daily dose of 2 mg reduced 24-hour mean systolic blood pressure by approximately 16.6 mmHg from baseline, producing a 14.0 mmHg placebo-adjusted difference (p < 0.0001). Significant reductions were observed in both daytime and nighttime systolic blood pressure, with nighttime decreases of about 13.9 mmHg. Notably, 70.6% of patients in the Baxdrostat arm achieved a 24-hour mean systolic pressure below 130 mmHg at Week 12, compared with only 16.7% in the placebo arm (OR = 15.2; NNT ≈ 2).

Overall tolerability was favorable. The most common adverse events included hyperkalemia, hypotension and headache. Reports of hyperkalemia varied between trials: in BaxHTN, confirmed cases were infrequent, while in Bax24, a small proportion of subjects discontinued due to increased potassium levels (approximately 4.6%). No clinically significant adrenal insufficiency events were observed. Baxdrostat’s highly selective inhibition of aldosterone biosynthesis reduces aldosterone production while largely sparing cortisol pathways, mitigating the “off-target inhibition” risks seen in earlier ASI candidates.

Experts across academia and industry generally view Baxdrostat’s results as reinforcing the central role of aldosterone in resistant hypertension. The magnitude of blood-pressure reduction appears to exceed that typically seen with conventional first-line antihypertensive agents or existing mineralocorticoid receptor antagonists (MRAs). Given the substantial global burden of hypertension and the meaningful proportion of patients with resistant disease, Baxdrostat could fill a significant therapeutic gap if approved and potentially signal a paradigm shift from broad-spectrum antihypertensive strategies toward targeted suppression of aldosterone synthesis.

Beyond hypertension, AstraZeneca is also advancing Baxdrostat for chronic kidney disease, heart failure and primary aldosteronism. The company maintains a positive outlook on its future market potential. Regulatory decisions will depend on the FDA’s review outcome, and further investigation is needed to clarify differential responses across baseline renin or aldosterone profiles, long-term safety considerations and real-world generalizability.

A summary of the publicly available core Chinese-origin patents for Baxdrostat is provided in the following table.